James Wassil’s Post

We are thrilled to share that we have been recognized by Great Place to Work as one of the Best Small and Medium Workplaces in the Bay Area for the second year in a row! This year, we are #11 overall and the #1-ranked biotech in our category. At Vaxcyte, we lead with heart to achieve bold goals and are grateful to the entire team for making this company such a special place to work. Check out our Great Place to Work page: https://lnkd.in/gxPHBaSb    Interested in joining our growing team? Learn more at vaxcyte.com/job-listings/ #GreatPlacetoWork #culture #biotech

The Lancet Infectious Diseases published results from the Phase 1/2 clinical proof-of-concept (POC) study assessing the safety, tolerability and immunogenicity of our lead candidate, VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) designed to prevent invasive pneumococcal disease (IPD), in adults. The study results included in this publication, as well as an independent commentary, highlight the potential best-in-class profile of VAX-24 while also validating our carrier-sparing, cell-free platform. Despite the availability of pneumococcal vaccines, the bacteria associated with IPD continues to be a major driver of deaths and Antimicrobial Resistance. This is among the reasons the public health community continues to emphasize the need for vaccines that provide broader coverage against IPD. https://lnkd.in/gpxM5Eyt https://lnkd.in/gTnnQCXp

Today, we initiated the first adult clinical study of VAX-31, which is the broadest-spectrum pneumococcal conjugate vaccine (PCV) to enter the clinic, with the potential to protect against approximately 95% of invasive pneumococcal disease circulating in the U.S. adult population. Leveraging the foundation established by our lead PCV candidate, VAX-24, we believe we have an opportunity to deliver a best-in-class PCV franchise that provides the broadest-spectrum of coverage and improved immune responses compared to the standard-of-care in adults today. Congratulations to the Vaxcyte team on achieving this important milestone! Learn more: https://lnkd.in/g6JuvPnY #vaccines #biotechnology #protecthumankind

We are excited to announce a new commercial manufacturing agreement with Lonza, expanding our long-term collaboration to support the potential global commercialization of our pneumococcal conjugate vaccine (PCV) candidates, VAX-24 and VAX-31. Following the successful completion of our VAX-24 Phase 2 adult studies, and as we prepare for Phase 3 clinical studies, we are putting into motion the key steps required to establish large-scale and long-term commercial manufacturing capacity for our PCV candidates. Learn more: https://lnkd.in/g9YMgArN  #vaccines #biotechnology #protecthumankind

We are excited to share that the U.S . Food and Drug Administration (FDA) has cleared our adult Investigational New Drug (IND) application for VAX-31, which will be the broadest-spectrum PCV to enter the clinic. This milestone represents an important step toward our goal of building a best-in-class PCV franchise. VAX-31 leverages our cell-free platform to expand coverage against approximately 95% of the serotypes that currently cause invasive pneumococcal disease (IPD) in the U.S. adult population. This is especially important given IPD contributes to high-case fatality rates, antibacterial resistance and meningitis, all of which are particularly concerning in the older adult population. Learn more: https://lnkd.in/gc8h5vzG #vaccines #biotechnology #protecthumankind

We are excited to announce that the ongoing Phase 2 study of VAX-24, our lead, broad-spectrum 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), is advancing to the second and final stage of the study. The public health community has continued to affirm the need for broader-spectrum PCVs given the burden of disease in the pediatric population, and VAX-24 - the broadest-spectrum PCV in U.S. clinics today - includes serotypes that cover a significant portion of IPD currently in circulation that are associated with high case-fatality rates, antibiotic resistance and meningitis. Learn more: https://lnkd.in/gvegzgPW  #biotechnology #vaccines #publichealth

How can Vaccine use slow antibiotic resistance? Can we develop vaccines that target AMR bacteria to slow the spread. A great panel today on this topic with some leaders in R&D from large and small companies alike. Jomana Musmar, MS, PhD James Wassil Leonard Friedland Dr Joseph P Sevilla at Harvard and Victor Nizet

We’re proud to share that our very own James Wassil will be speaking at #BIO2023 on a panel of experts discussing how we can fight antimicrobial resistance with vaccine innovation. For those attending BIO this year, we encourage you to check out the panel. Details are found here: https://lnkd.in/g-uaxeyg #biotechnology #vaccines #innovation